Rigel Pharmaceuticals Inc. (New) RIGL
$42.45
-0.31%
at last close
Market Cap$795.39 million
P/E Ratio2.51
Div Yield—
Volume502.5K
52-Week Range
$18.65$52.24
Analyst Ratings
- Consensus
- Moderate Buy — 3 Buy · 2 Hold · 0 Sell (5 analysts)
- Avg. Price Target
- $59.00 (+39.0% upside)
Key Stats
- Today's Range
- $42.08 – $43.26
- 50-Day Range
- $29.61 – $43.99
- 52-Week Range
- $18.65 – $52.24
- Volume
- 502K shs
- Average Volume
- 338K shs
- Market Cap
- $795.39 million
- P/E Ratio
- 2.51
- Dividend Yield
- —
Valuation
- P/E Ratio
- 2.51
- Price / Book
- 1.87
- Price / Sales
- 2.87
Short Interest
- Short Interest
- 42.81%
- Days to Cover
- 5.84
Financials (TTM)
- Revenue
- $276.79 million
- Net Income
- $321.91 million
- Net Margin
- 116.30%
- Return on Equity
- 75.67%
- Debt-to-Equity
- —
About Rigel Pharmaceuticals Inc. (New)
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
Related Stocks
Compare head-to-head: RIGL vs LLY·RIGL vs JNJ·RIGL vs ABBV·RIGL vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.